The Most Up-to Date Microsoft070-411Exam Questions 700-505 700-501 648-232 640-911 070-462 3I0-012 070-463 Latest117-202Questions - LPIC Level 2 117-202 Certification RCDD-001 070-685 200-101 070-412 Download Cisco400-101Exams - Free VCE Exams For All 70-243 200-120 100-105 Latest 117-201 Questions - LPIC Level 2 117-201Certification C9530-404 070-480 70-487 300-207 4A0-100 600-199 350-018 070-410 100-101 CCNP Routing and Switching SWITCH300-115Official Cert M70-201 C2020-703 070-347 70-412 70-417 JN0-643 E20-690 70-410 642-747 70-331 70-413 Pass MICROSOFT70-411exam - test questions 352-001 210-260 SY0-401 200-125 300-320 200-310 CISSP PMP 300-075 210-065 Cisco CCNA Collaboration210-060CICD: Welcome to Cisco 70-534 70-532 EX200 1Z0-803 210-451 300-101 Latest HP0-S42 Questions - ASEHP0-S42Certification 300-206 070-346 70-461 HP0-S41 640-916 CompTIA Network+N10-006 EX300 1Z0-434 1Z0-060 C_HANAIMP151 C_TAW12_740 AWS-SYSOPS 70-346 2V0-620 300-070 C_HANATEC151 LatestE05-001Questions - Cloud Architect (EMCCA) JN0-360 2V0-641 642-999 70-697 300-208 FC0-U51 Latest PW0-071 Questions - CWTS PW0-071Certification C_GRCAC_10 IIA-CIA-PART3 642-732 500-260 C_HANAIMP142 98-366 1Z0-047 70-496Microsoft Real Exam Questions - 100% Free VCE Files 70-533 810-403 642-998 70-470 JN0-343 CCNP Wireless642-742New Updated Cisco 642-742 Study 220-802 70-486 642-035 JN0-692 1Z0-470 CAS-002 Cisco 642-883 Dumps |642-883Exam Questions PGMP 200-105 1Z0-051 642-887 070-688 156-215.77 400-351 H12-211Exam Huawei H12-211 Test Questions PDF C2090-930 102-400 70-696 SK0-004 101-400 1Z0-061 ADM-211 300-360 CCNP Data Center642-996Latest Version Cisco 642-996 With New 400-051 70-646 4A0-107 1Z0-574 74-343 700-039 1Z0-435Oracle Business Process Management Suite 1Y0-401 1Y0-201 200-355 74-344 300-135 Download300-370Exam PDF Questions Answers 712-50 070-496 C2090-311 300-080 640-875 AX0-100Axis Communications Real Exam Questions

Press Releases

by Sophiris Admin

In: Press Releases

No comments

San Diego, California and Vancouver, British Columbia, August 16, 2012 — Sophiris Bio Inc. (TSX: SHS) today announced the appointment of Randall E. Woods as Chief Executive Officer effective August 16, 2012. Mr. Woods brings almost 40 years of relevant industry experience to Sophiris, including past roles as CEO at Sequel Pharmaceuticals, NovaCardia Inc., and Corvas International. Mr. Woods takes the helm as Sophiris prepares to initiate a pivotal Phase 3 trial for its lead compound, PRX302, a highly targeted treatment for benign prostatic hyperplasia (BPH or enlarged prostate).

Mr. Woods’ appointment is the final step of an operational realignment that began in 2011, led by Executive Chairman and President Lars Ekman, M.D., Ph.D., to focus on the development of PRX302 for BPH. Since relocating to San Diego, Sophiris has recruited a management team that has achieved more than twenty drug approvals, including blockbuster pharmaceuticals.

“Randy’s blend of executive experience in biotech research and development, pharmaceutical sales and marketing, coupled with successful fundraising and value creation makes him an ideal fit for leading Sophiris into the next phase of growth, beginning with advancing PRX302 into pivotal trials later this year,” said Dr. Lars Ekman, Executive Chairman and President of Sophiris.

“Nearly every man over the age of 60 suffers from BPH, yet current treatments either lack sustained relief of symptoms or come with unwanted side effects,” added Mr. Woods. “Based on the clinical data available to date PRX302 has shown meaningful clinical improvements with an attractive safety profile and presents a very special opportunity for addressing a significant market need for men with BPH.”

Prior to joining Sophiris, Mr. Woods was President and CEO of Sequel Pharmaceuticals, a spin-out of NovaCardia developing a potential treatment for atrial fibrillation. Mr. Woods was previously the President and CEO of NovaCardia, a pharmaceutical company focused on cardiovascular diseases until its acquisition by Merck & Co for $350 million in 2007. Prior to NovaCardia, Mr. Woods was President and CEO of Corvas International, a publicly held biopharmaceutical company focused on cardiovascular disease and cancer until its acquisition by Dendreon in 2003. Before joining Corvas, he served as President of Boehringer Mannheim’s U.S. Pharmaceutical operations, and spent 20 years at Eli Lilly & Company in various sales and marketing positions. Mr. Woods is a past Chairman for the Advisory Board of UC San Diego’s Sulpizio Family Cardiovascular Center and is a past Chairman of the Board of Directors for BIOCOM, a life science industry association in Southern California. Mr. Woods serves on the Board of Arena Pharmaceuticals and is Chairman of the Board for Sorbent Therapeutics. He received his B.S. in Biology and Chemistry from Ball State University and an MBA in Marketing from Western Michigan University.

About BPH

BPH is a $5 billion market with more than 4 million patients treated each year in the U.S. alone. Despite available medical treatments and surgical options, no single solution provides quick, long-term relief of symptoms without serious unwanted side effects. Pharmaceutical product sales in the U.S. for BPH are $4 billion annually, however they lack sustainable efficacy and are associated with undesirable side effects including sexual dysfunction. More aggressive treatment options include invasive surgical procedures that may be successful at treating BPH but can also result in nerve damage and sexual dysfunction.

About PRX302

PRX302 is designed to be a single treatment for the long-term relief of BPH symptoms, such as restricted urinary flow from enlarged prostate, without causing sexual dysfunction or sacrificing quality of life.
PRX302 is highly targeted to prostate tissue. It is delivered directly to the prostate tissue via localized injection and it is activated selectively by active Prostate Specific Antigen (PSA) found only in prostate tissue. PRX302 has shown meaningful improvements in the International Prostate Symptom Score (IPSS) and urinary flow (Qmax) at 3 and 6 months in a randomized controlled Phase IIb trial (TRIUMPH study). IPSS has been a primary endpoint and Qmax has been a secondary or co-primary endpoint for prior BPH drug approvals. To date 126 patients with BPH have been treated with PRX302, and no drug related sexual adverse events have been reported in the studies completed.

About Sophiris

Sophiris Bio Inc. is a urology company developing a late-stage, highly targeted treatment for benign prostatic hyperplasia (BPH or enlarged prostate), an unsatisfied market with blockbuster potential. PRX302, the company’s lead candidate for BPH, is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Sophiris is planning to begin a pivotal trial by the end of 2012. Sophiris is advised by world-leading urologists, backed by experienced investors, and led by a team that has achieved more than twenty drug approvals including several blockbusters. For more information, please visit www.sophirisbio.com.

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Sophiris’ current beliefs as well as assumptions made by and information currently available to Sophiris and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Sophiris in its public securities filings; actual events may differ materially from current expectations. Sophiris disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For Further Information Contact:

Lauren Glaser
Investor Relations
The Trout Group
646-378-2972
lglaser@troutgroup.com

James Beesley
Investor Relations
Sequoia Partners
778-389-7715
james@sequoiapartners.ca

Michael Moore
Investor Relations
Equicom Group
619-467-7067
mmore@equicomgroup.com

Jason I. Spark
Canale Communications, Inc.
619-849-6005
jason@canalecomm.com

Download full press release »

070-411 , 700-505 , 700-501 , 648-232 , 640-911 , 070-462 , 3I0-012 , 200-101 , C2020-703 , 070-347 , 070-463 , 070-412 , 117-202 , 400-101 , 70-412 , 70-243 , 70-417 , 200-120 , 100-105 , 117-201 , C9530-404 , 070-480 , 70-487 , 300-207 , JN0-643 , 4A0-100 , 600-199 , E20-690 , 350-018 , 070-410 , 70-410 , 100-101 , 642-747 , 70-331 , 70-413 , 70-411 , 352-001 , 210-260 , SY0-401 , 200-125 , 300-320 , 200-310 , CISSP , 300-115 , PMP , 300-075 , 210-065 , 210-060 , 70-534 , 70-532 , EX200 , 1Z0-803 , 210-451 , 300-101 , HP0-S42 , 300-206 , 070-346 , 70-461 , HP0-S41 , 640-916 , N10-006 , EX300 , 1Z0-434 , 1Z0-060 , C_HANAIMP151 , C_TAW12_740 , AWS-SYSOPS , 70-346 , 2V0-620 , 300-070 , C_HANATEC151 , E05-001 , JN0-360 , 2V0-641 , M70-201 , 642-999 , 70-697 , 300-208 , FC0-U51 , PW0-071 , C_GRCAC_10 , IIA-CIA-PART3 , 642-732 , 500-260 , C_HANAIMP142 , 98-366 , 1Z0-047 , 70-496 , 70-533 , 810-403 , 642-998 , 70-470 , JN0-343 , 642-742 , 220-802 , 70-486 , 642-035 , JN0-692 , 1Z0-470 , CAS-002 , 642-883 , PGMP , 200-105 , 1Z0-051 , 642-887 , 070-688 , 156-215.77 , RCDD-001 , 400-351 , H12-211 , C2090-930 , 102-400 , 70-696 , 070-685 , SK0-004 , 101-400 , 1Z0-061 , ADM-211 , 300-360 , 642-996 ,